Medicamentsen-ligne vous propose les traitements dont vous avez besoin afin de prendre soin de votre santé sexuelle. Avec plus de 5 ans d'expérience et plus de 90.000 clients francophones, nous étions la première clinique fournissant du acheter levitra original en France à vente en ligne et le premier vendeur en ligne de Viagra dans le monde. Pourquoi prendre des risques si vous pouvez être sûr avec Medicamentsen-ligne - Le service auquel vous pouvez faire confiance.

Microsoft word - recovery -schizophrenia - bipolar.doc

Is There a Psychopharmacology of Recovery from
Schizophrenia?
Medical parallel:
treatment of complicated medical
illness such as cancer requires clinician to be good
strategist and good technician; same applies to
complicated psychiatric illness such as schizophrenia
Current challenges in treating severe mental illness:
cure unlikely for most patients;
-more medication choices than ever,
-more chances to “get it right”
-more chances to “get it wrong”;
-controversy about degree to which newer medications
can improve outcome;
-newer antipsychotic medications still have burden of side
effects different from that of older antipsychotics (eg,
newer antipsychotics have reduced neurologic burden but
increased metabolic burden)
Treatment models in schizophrenia:
-
phase-of-illness model
goal of keeping patient stable and avoiding relapse;
-hierarchical model,
-treatment progresses in linear fashion, from stabilizing
patient to reducing burden of treatment and/or burden of
disease to recovery (no consensus on what constitutes
recovery in schizophrenia; clinician, patient and family,
and insurance company have differing definitions)
Treatment goals in schizophrenia:
remission—concept derived from treatment of affective
disorders, in which it means patient has no symptoms; in
schizophrenia, it means symptoms may be present but do
not interfere with patient’s functioning or quality of life;
recovery—defined by President’s New Freedom
Commission on Mental Health as “process in which
people are able to live, work, learn, and participate fully
in their communities; for some individuals,
recovery is the ability to live a fulfilling and productive
life despite a disability”; ie, patient may experience
symptoms but still lead full productive life
Recovery model in schizophrenia: key assumptions
-deterioration not inevitable
- stability marks beginning, not end, of treatment;
-goals are for achieving individual’s health rather than
comparing him or her to others with persistent illness;
-specific goals chosen by patient, not family or clinician
Reasons recovery-oriented treatment realistic in
schizophrenia:
-ascendancy of neurodevelopmental model over
neurodegenerative model;
-evidence for continued improvement over and above
stabilization with newer medications;
-evidence that psychosocial interventions can reduce
persistent symptoms;
-consistency of differences of side-effect profiles across
antipsychotic treatment options
Recovery-oriented approach to medication
management:
-patient sets goals and frustrations;
-match frustrations with target symptom that can be
treated and
-work with patient to identify priority symptom to
treat
-advise patient not to stop medications
-Persistent positive symptoms: optimize current
medication regimen before changing medications;
-anticholinergics attenuate response to antipsychotics; -
-antidepressants delay or attenuate response to
antipsychotics;
-rule out nonpharmacologic causes of poor treatment
response
Cognition: news mixed; Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) study showed that
-newer antipsychotics have limited benefits on cognition,
relative to older antipsychotics;
-anticholinergic estimated to account for ≈50% of
cognitive dysfunction in patients taking anticholinergic; -
-when asked which symptoms most frustrating, most
patients say cognitive symptoms and affective symptoms
trump positive symptoms and negative symptoms;
-first consideration is not to make cognitive symptoms
worse
-Depression: newer antipsychotics better for attenuating
comorbid depression; if depression continues, consider
whether antidepressant or psychosocial intervention better
adjunct, remembering that antidepressants can aggravate
psychosis in some patients
Adverse events and burden of treatment: theoretically,
antipsychotic response can be achieved without side
effects; difficult and requires good strategy;
extrapyramidal side effects and sedation not necessary
components of treatment;
-assess level of distress and risks of treatment modalities
New Treatment Options for Bipolar Disorder
Monotherapy:
in registration studies, in both mania and
depression, antipsychotics provide 20% benefit (on
average) over placebo; average number of medications in
patients with bipolar disorder is 5
Divalproex (Depakote): monotherapy—studies found
that “loading divalproex could be effective,” and loading
strategy used in registration studies for divalproex
extended release (ER); starting dosage 25 mg/kg per day,
rounded up to nearest 500, then increased by another 500
mg on day 3; combination therapy— in American
approach, foundational therapy is mood stabilizer (lithium
or divalproex), with atypical antipsychotic added; in
European approach, foundational therapy is antipsychotic,
with mood stabilizer added; in European trial, valproate
added to antipsychotic achieved extra benefit of 20% to
25% over antipsychotic monotherapy
Carbamazepine (Tegretol): monotherapy—benefit
≈20% over placebo; starting dosage 400 mg/day in
divided doses produced “fair bit of toxicity”; suggest that
starting with 200 mg/day and increasing by 200 mg every
other day decreases toxicity; carbamazepine lowers blood
levels of “almost everything” except maybe ziprasidone;
combination therapy
in trial of acute mania where olanzapine (Zyprexa) or
placebo
added to carbamazepine, no additional benefit seen;
in study where risperidone added to carbamazepine, 40%
decrease in risperidone blood levels, and patients on
carbamazepine had to be censored to see add-on
risperidone separate from placebo and other mood
stabilizers; carbamazepine should have no
pharmacokinetic interaction with lithium, excreted
renally,
lithium, even olanzapine, failed to show additional benefit
when added to carbamazepine
Bipolar disorder: patients symptomatic about half the
time, and depression more common than mood elevation;
Systematic Treatment Enhancement Program (STEP)
showed in depressed patients that adding antidepressant to
mood stabilizer does not add much benefit over mood
stabilizer alone, and mood stabilizer alone achieved only
≈25% response; with mood stabilizer as monotherapy
in depressed patients, perhaps adding antidepressant
later; if antidepressant does not work, try atypical
antipsychotic
Pramipexole (Miramex): 2 trials show it may work as add-on, but only 22 patients total, and “there were some mood switches”; speaker starts with 0.125 mg at bedtime and increases every 4 days to 1.75 mg; “look out for nausea” Other add-ons: 1 trial showed 22% response rate to modafinil (Provigil), with 4.9% switch rate; gabapentin shown not to be effective as primary treatment for mania or for treatmentresistant rapid-cycling bipolar disorder, but may be useful in comorbid conditions such as anxiety or pain Lamotrigine: in trials, lamotrigine worked well in terms of response rate, but placebo worked well also; not indicated for acute bipolar depression or acute mania; may be effective in preventing recurrent depression; combination of lamotrigine and lithium may prevent depressive and manic episodes; in study, lamotrigine effective in treatment-resistant rapid cycling Topiramate Topomax): ineffective in acute mania, but patients lost weight; may be effective in treating comorbid disorders such as eating disorders, alcohol dependence, and migraine; can cause metabolic acidosis Zonisamide (Zonegran): produced weight loss in obese
people with no psychiatric disorder and in obese people
with euthymic
medicated bipolar disorder; long half life; cannot be used
by patients with sulfonamide allergy; weight loss and
tolerability adequate in one third of patients, intolerance
in onethird, and it “just doesn’t work” one-third;
metabolic acidosis can occur
Oxcarbazepine (Trileptal): “data not too encouraging”;
consider oxcarbazepine if patient has failed
carbamazepine or is too unreliable to comply with blood
testing associated with carbamazepine
Atypical antipsychotics: all seem to work in mania;
clozapine is only atypical antipsychotic not approved by
Food and Drug Administration (FDA) for use in bipolar
mania; clozapine helpful if patient unable to sleep, but
requires blood testing because of risk for agranulocytosis
Risperidone: response ≈20% compared to placebo; if
added to lithium or divalproex, additional benefit seen
Olanzapine: response rate 20% to 25%; doses in trials 10
mg/day to 20 mg/day; in head-to-head trial with
divalproex, olanzapine slightly better in efficacy, but
divalproex slightly better in tolerability;
in head-to-head trial with lithium, olanzapine slightly better in relapsing mania, but associated with more weight gain than lithium Olanzapine plus fluoxetine combination: response “so-so” with 7.5 mg of olanzapine and 40 mg of fluoxetine per day; “if you absolutely have to use an antidepressant in bipolar depression and you want to do evidence-based medicine, this is what you would do”; in head-to-head trial with lamotrigine, combination had 9% response rate vs 7% weight gain Quetiapine (Sertoquel): response rate ≈17%; must be titrated to avoid hypotension Other atypical antipsychotics: ziprasidone (Geodon) and aripiprazole (Abilify), “we know [they] work in acute mania”; aripiprazole has maintenance indication; asenapine (Saphris)—separated from placebo on primary-outcome measure but not on response rate Emerging uses for atypical antipsychotics in bipolar disorder: primary therapies—olanzapine for mania, maintenance, and, when combined with fluoxetine, depression; risperidone, ziprasidone, and asenapine for mania; quetiapine for mania and depression; aripiprazole for
mania and maintenance;
adjunctive therapies—olanzapine and risperidone
for mania; quetiapine for mania and maintenance;
clozapine for treatment resistance
Conclusions: many new agents with diverse mechanistic
efficacy and side-effect profiles in development; new
anticonvulsants as class not effective in acute mania and
have variable efficacy in bipolar disorders and comorbid
conditions; newer antipsychotics as class effective in
acute mania and show emerging efficacy in acute
depression and maintenance

Source: http://nationsnet.com/naminc/Conference%202009/presentation_pdfs/Recovery%20-Schizophrenia%20-%20Bipolar.pdf

Kid_9418.tex

Kidney International, Vol. 67, Supplement 94 (2005), pp. S70–S74 Prevention of renal failure: The Malaysian experience LAI SEONG HOOI, HIN SENG WONG, and ZAKI MORAD Department of Medicine, Sultanah Aminah Hospital Johor Baru, Johor, Malaysia; and Department of Nephrology, Hospital KualaLumpur, Kuala Lumpur, Malaysia Prevention of renal failure: The Malaysian experience. Re- the face of

mentalhealthupdate.com

Sildenafil Treatment of Women With Antidepressant-Associated Sexual Dysfunction A Randomized Controlled Trial Context Antidepressant-associated sexual dysfunction is a common adverse effect that frequently results in premature medication treatment discontinuation and for whichno treatment has demonstrated efficacy in women. Objective To evaluate the efficacy of sildenafil for sexual dysf

Copyright © 2010-2014 Pharmacy Pills Pdf